Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors Academic Article uri icon


MeSH Major

  • Immunotherapy, Adoptive
  • Major Histocompatibility Complex
  • Neoplasms
  • Precursor Cells, T-Lymphoid
  • Transfection


  • We present a strategy for adoptive immunotherapy using T-lineage committed lymphoid precursor cells generated by Notch1-based culture. We found that allogeneic T-cell precursors can be transferred to irradiated individuals irrespective of major histocompatibility complex (MHC) disparities and give rise to host-MHC restricted and host-tolerant functional allogeneic T cells, improving survival in irradiated recipients as well as enhancing anti-tumor responses. T-cell precursors transduced to express a chimeric receptor targeting hCD19 resulted in significant additional anti-tumor activity, demonstrating the feasibility of genetic engineering of these cells. We conclude that ex vivo generated MHC-disparate T-cell precursors from any donor can be used universally for 'off-the-shelf' immunotherapy, and can be further enhanced by genetic engineering for targeted immunotherapy.

publication date

  • April 2008



  • Academic Article



  • eng

PubMed Central ID

  • PMC2731996

Digital Object Identifier (DOI)

  • 10.1038/nbt1395

PubMed ID

  • 18376399

Additional Document Info

start page

  • 453

end page

  • 61


  • 26


  • 4